Locoregional treatment of primary tumor in synchronous metastatic head and neck squamous cell carcinomas

References

• Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016;91(3):386–396.
   PubMed Web of Science ®Google Scholar
• Guigay J, Aupérin A, Fayette J, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463–475.
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–1928.
   PubMed Web of Science ®Google Scholar
• Ferrand F, Malka D, Bourredjem A, et al. Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601. Eur J Cancer. 2013;49(1):90–97.
   PubMed Web of Science ®Google Scholar
• Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417–427.
   PubMed Web of Science ®Google Scholar
• Shiarli A-M, McDonald F, Gomez DR. When should we irradiate the primary in metastatic lung cancer? Clin Oncol. 2019;31(12):815–823.
   Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830–2838.
   PubMed Web of Science ®Google Scholar
• Coatesworth AP, Tsikoudas A, MacLennan K. The cause of death in patients with head and neck squamous cell carcinoma. J Laryngol Otol. 2002;116(4):269–271.
   PubMed Web of Science ®Google Scholar
• Slootweg PJ, Bolle CW, Koole R, et al. Cause of death in squamous cell carcinoma of the head and neck an autopsy study on 31 patients. J Craniomaxillofac Surg. 1992;20(5):225–227.
   PubMed Web of Science ®Google Scholar
• Patel TD, Marchiano E, Chin OY, et al. Utility of surgery/radiotherapy in distant metastatic head and neck squamous cell carcinoma: a population-based approach. Otolaryngol Head Neck Surg. 2016;154(5):868–874.
   PubMed Web of Science ®Google Scholar
• Kabarriti R, Baliga S, Ohri N, et al. Radiation therapy for patients with newly diagnosed metastatic head and neck squamous cell carcinoma. Head & Neck. 2018;41(1):130–138. 10.1002/hed.25476.
   PubMed Web of Science ®Google Scholar
• Zumsteg ZS, Luu M, Yoshida EJ, et al. Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: an analysis of the national cancer data base: local treatment in metastatic HNSCC. Cancer. 2017;123(23):4583–4593.
   PubMed Web of Science ®Google Scholar
• Rambeau A, Bastit V, Thureau S, et al. Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma. Oral Oncol. 2019;93:46–51.
   PubMed Web of Science ®Google Scholar
• Vermorken J, Mesia R, Rivera F, et al. Platinum-Based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–1127.
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–2058.
   PubMed Web of Science ®Google Scholar
• Leeman JE, Patel S, Anderson ES, et al. Long-term survival in oligometastatic head and neck cancer. Int J Radiat Oncol Biol Phys. 2017;99(2):S138.
   Google Scholar
• Mirghani H, Leroy C, Chekourry Y, et al. Smoking impact on HPV driven head and neck cancer’s oncological outcomes? Oral Oncol. 2018;82:131–137.
   PubMed Web of Science ®Google Scholar
• Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.
   PubMed Web of Science ®Google Scholar
• Pike LRG, Hwang WL, Royce TJ, et al. HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx. Oral Oncol. 2018;86:69–74.
   PubMed Web of Science ®Google Scholar
• Shuryak I, Hall EJ, Brenner DJ. Optimized hypofractionation can markedly improve tumor control and decrease late effects for head and neck cancer. Int J Radiat Oncol Biol Phys. 2019;104(2):272–278.
   PubMed Web of Science ®Google Scholar
• Villaflor VM, Melotek JM, Karrison TG, et al. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016;27(5):908–913.
   PubMed Web of Science ®Google Scholar